Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV Genotype 1 and 4 Infected Patients

Neben Steven; Pavlicek Adam; Patick Amy; Huang Michael

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV Genotype 1 and 4 Infected Patients

【24h】

Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV Genotype 1 and 4 Infected Patients

机译：预先存在的HCV抗性相关变体的患病率和对RG-101的对治疗结果的影响与HCV基因型1和4名感染患者的直接作用抗病毒组合

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases 》 |2016年第s1期| 共2页
作者
Neben Steven; Pavlicek Adam; Patick Amy; Huang Michael;
展开▼
作者单位

Regulus Therapeut San Diego CA USA;

Regulus Therapeut San Diego CA USA;

Regulus Therapeut San Diego CA USA;

Regulus Therapeut San Diego CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV Genotype 1 and 4 Infected Patients [J] . Neben Steven, Pavlicek Adam, Patick Amy, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016 ,第S1期

机译：预先存在的HCV抗性相关变体的患病率和对RG-101的对治疗结果的影响与HCV基因型1和4名感染患者的直接作用抗病毒组合
2. Analysis of HCV Variants in the MAGELLAN-1 Part 1 Study: ABT-493 and ABT-530 Combination Therapy of Genotype 1-Infected Patients Who Had Failed Prior Direct Acting Antiviral-Containing Regimens [J] . Ng Teresa, Pilot-Matias Tami, Tripathi Rakesh, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016 ,第S1期

机译：Magellan-1第1部分的HCV变体分析：ABT-493和ABT-530组合治疗基因型1感染患者，其未发生含有含抗病毒方案的失败
3. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data [J] . Zhi-wei Chen, Hu Li, Hong Ren, Scientific reports. . 2016 ,第1期

机译：预先存在的HCV变体对直接作用抗病毒药物（DAAS）的全局患病率：挖掘Genbank HCV基因组数据
4. Prevalence of Skin diseases among Hepatitis C virus infected patients and their association with HCV infection in Islamabad, Pakistan [C] . Zujaja tul Misbah, Lubaba tul Uzma, Kanwal Shaheen, International Bhurban Conference on Applied Sciences and Technology . 2019

机译：巴基斯坦伊斯兰堡的丙型肝炎病毒感染患者皮肤病患病率及其与HCV感染的关系
5. The Distribution of Change over Time in Metabolic, Inflammatory, and Immune Parameters in HCV-monoinfected and HIV/HCV-coinfected Patients Cured of Hepatitis C Virus by Direct-Acting Antiviral Therapy [D] . Emmanuel, Benjamin. 2018

机译：通过直接作用抗病毒治疗，在HCV-单染料和HCV / HCV / HCV-焦收的患者中的代谢，炎症和免疫参数随时间随时间的分布，通过直接作用抗病毒治疗治愈丙型肝炎病毒
6. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients [O] . Zhanyi Li, Ying Liu, Ying Zhang, 2006

机译：丙型肝炎病毒基因型6a感染患者中丙型肝炎病毒直接作用抗病毒药物的天然耐药性变异体
7. Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients [O] . Zhi-wei Chen, Xi-chen Pang, Zhao Li, 2017

机译：Pegylated-Interferon Plus利巴韦林治疗不会改变抗性相关取代的患病率，在HCV基因型1A患者中的直接作用抗病毒

Prevalence of Pre-Existing HCV Resistance-Associated Variants and Impact on Treatment Outcome with RG-101 in Combination with Direct Acting Antivirals in HCV Genotype 1 and 4 Infected Patients

著录项

相似文献

相关主题

期刊订阅